Theranova Randomized, Controlled, Trial (RCT) in China

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 323 participants.

Also called NCT05309291

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 323 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05309291
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05309291. Randomized; no masking; primary purpose treatment. Start 2022-06-22 (actual); primary completion 2023-07-06 (actual). Results posted on 2024-10-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Theranova Randomized, Controlled, Trial (RCT) in China
Acronym
ROCKet
Condition
Chronic Kidney Failure
Condition
Acute Kidney Failure
Intervention (Device)
Theranova 400 Dialyzer
Intervention (Device)
FX 800 Dialyzer
Lead sponsor
Vantive Health LLC (class: industry)
Collaborator
Baxter Healthcare Corporation (class: industry)

Record details

Record id
cardio:ct-nct05309291
Content hash
966b2ada07b16293b6254d1b2d88a346f32532ada4e448be94ece7aea37f780e